PT-141
Also known as Bremelanotide
Studied for: desire signaling
PT-141 is studied for its role in the signaling pathways tied to desire and motivation. Research focuses on central melanocortin receptors rather than the vascular system.
Last reviewed September 26, 2026
How it is thought to work
Research describes PT-141 as an agonist at melanocortin receptors in the central nervous system, studied for influence on signaling upstream of vascular response.
- Central SignalingStudied for activity at melanocortin receptors within the central nervous system, associated with motivation and arousal circuits.
- Non-Vascular PathwayResearch explores a mechanism upstream of vascular response, working through neural signaling rather than circulation.
- Route studied
- Subcutaneous
- Research status
- Approved analog
Bremelanotide, the name under which PT-141 is also known, has received regulatory approval for hypoactive sexual desire disorder, and its safety profile has been reported across a clinical development program that included phase 3 trials.
Research
What the research covers
What research examines
- Hypoactive sexual desire disorder in women
- Central melanocortin receptor signaling
- Desire and motivation pathways
- Neural mechanisms upstream of vascular response
Reported effects in studies
- Safety profile evaluated across a clinical development program that included phase 3 randomized controlled trials
- Specific adverse events are not summarized on this page; the published phase 3 safety analysis is the primary reference
- Safety data for research contexts outside the approved indication are limited
Studied range
What research protocols have used
Research protocols have used 500–2,000 mcg per administration, as needed.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- Kisspeptin-10Kisspeptin sits at the top of the reproductive hormone cascade. Research examines its role in initiating GnRH release, and the overlap between that signaling and circuits tied to desire.Read profile$59
- HCGHCG is a glycoprotein hormone studied for its activity at the luteinizing hormone receptor, and for its role in research on the hypothalamic-pituitary-gonadal axis.Read profile$79
Studies
Cited research
- Bremelanotide: First Approval.
Drugs · 2019 · Review · PMID 31429064
- Safety Profile of Bremelanotide Across the Clinical Development Program.
Journal of women's health (2002) · 2022 · RCT · PMID 35147466
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Neurology international · 2022 · Review · PMID 35076581
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
The Annals of pharmacotherapy · 2020 · Systematic review · PMID 31893927
- PT-141 Palatin.
Current opinion in investigational drugs (London, England : 2000) · 2004 · Review · PMID 15134289
FAQ
Questions about PT-141
PT-141, also known as Bremelanotide, is a peptide studied for its role in signaling pathways tied to desire and motivation. Research focuses on central melanocortin receptors rather than on the vascular system. Bremelanotide has been the subject of multiple reviews and a clinical development program, and published literature describes its regulatory approval for hypoactive sexual desire disorder. CoreX supplies PT-141 for laboratory research use only.
Research describes PT-141 as an agonist at melanocortin receptors in the central nervous system. These receptors are associated with motivation and arousal circuits. Rather than acting directly on circulation, the peptide is studied for influence on neural signaling that sits upstream of vascular response. This central, non-vascular mechanism is the main feature distinguishing it in the research literature on sexual-health pathways.
The most extensively studied area is hypoactive sexual desire disorder in women, which is the subject of several reviews and a phase 3 clinical program. Published reviews cover its physiology, assessment context, and clinical development history, including its first regulatory approval in 2019. Earlier work, including a 2004 review under the PT-141 name, examined its development as an investigational compound acting through central melanocortin signaling.
The safety profile of Bremelanotide has been analyzed across its clinical development program, including phase 3 randomized controlled trials, and that analysis is the primary published reference for adverse events. Specific adverse event rates are not summarized here. Safety data outside the approved clinical indication, including in research settings with different protocols, are limited, and findings from the clinical program should not be assumed to apply to every context.
Research protocols have used 500 to 2,000 mcg per administration, on an as-needed basis, via the subcutaneous route. These figures describe amounts reported in research settings and are not a recommendation for any individual. Each CoreX order ships with a protocol guide for laboratory reference. Researchers should consult the primary literature for the specific study designs in which these amounts were used.
Ask about PT-141
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- PT-141 vs Kisspeptin-10PT-141, also known as bremelanotide, and Kisspeptin-10 are both peptides studied in connection with desire and reproductive signaling, but they act at different points in the nervous and endocrine systems. Research describes PT-141 as an agonist at central melanocortin receptors, studied for influence on motivation and arousal circuits upstream of vascular response. Bremelanotide has received regulatory approval for hypoactive sexual desire disorder, and its safety profile has been reported across a clinical development program that included phase 3 trials. Kisspeptin-10 is described as acting on hypothalamic neurons to trigger GnRH release, initiating the hypothalamic-pituitary-gonadal cascade. Its literature is largely preclinical, spanning reproductive signaling, bone, cardiac, neuronal and metabolic models, and human safety data are limited.